Literature DB >> 22951447

CFTR, mucins, and mucus obstruction in cystic fibrosis.

Silvia M Kreda1, C William Davis, Mary Callaghan Rose.   

Abstract

Mucus pathology in cystic fibrosis (CF) has been known for as long as the disease has been recognized and is sometimes called mucoviscidosis. The disease is marked by mucus hyperproduction and plugging in many organs, which are usually most fatal in the airways of CF patients, once the problem of meconium ileus at birth is resolved. After the CF gene, CFTR, was cloned and its protein product identified as a cAMP-regulated Cl(-) channel, causal mechanisms underlying the strong mucus phenotype of the disease became obscure. Here we focus on mucin genes and polymeric mucin glycoproteins, examining their regulation and potential relationships to a dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR). Detailed examination of CFTR expression in organs and different cell types indicates that changes in CFTR expression do not always correlate with the severity of CF disease or mucus accumulation. Thus, the mucus hyperproduction that typifies CF does not appear to be a direct cause of a defective CFTR but, rather, to be a downstream consequence. In organs like the lung, up-regulation of mucin gene expression by inflammation results from chronic infection; however, in other instances and organs, the inflammation may have a non-infectious origin. The mucus plugging phenotype of the β-subunit of the epithelial Na(+) channel (βENaC)-overexpressing mouse is proving to be an archetypal example of this kind of inflammation, with a dehydrated airway surface/concentrated mucus gel apparently providing the inflammatory stimulus. Data indicate that the luminal HCO(3)(-) deficiency recently described for CF epithelia may also provide such a stimulus, perhaps by causing a mal-maturation of mucins as they are released onto luminal surfaces. In any event, the path between CFTR dysfunction and mucus hyperproduction has proven tortuous, and its unraveling continues to offer its own twists and turns, along with fascinating glimpses into biology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951447      PMCID: PMC3426818          DOI: 10.1101/cshperspect.a009589

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  240 in total

1.  Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B.

Authors:  Sara Kirkham; John K Sheehan; David Knight; Paul S Richardson; David J Thornton
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  Cystic fibrosis of the pancreas: involvement of MUC6 mucin in obstruction of pancreatic ducts.

Authors:  C J Reid; K Hyde; S B Ho; A Harris
Journal:  Mol Med       Date:  1997-06       Impact factor: 6.354

3.  Epidermal growth factor system regulates mucin production in airways.

Authors:  K Takeyama; K Dabbagh; H M Lee; C Agustí; J A Lausier; I F Ueki; K M Grattan; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Studying mucin secretion from human bronchial epithelial cell primary cultures.

Authors:  Lubna H Abdullah; Cédric Wolber; Mehmet Kesimer; John K Sheehan; C William Davis
Journal:  Methods Mol Biol       Date:  2012

Review 5.  Mucin exocytosis.

Authors:  P Verdugo
Journal:  Am Rev Respir Dis       Date:  1991-09

6.  Expression of cystic fibrosis transmembrane conductance regulator in human gallbladder epithelial cells.

Authors:  N Dray-Charier; A Paul; D Veissiere; M Mergey; J Y Scoazec; J Capeau; C Brahimi-Horn; C Housset
Journal:  Lab Invest       Date:  1995-12       Impact factor: 5.662

7.  IL-6 and IL-8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx epitopes in the human bronchial mucosa.

Authors:  Sophie Groux-Degroote; Marie-Ange Krzewinski-Recchi; Aurélie Cazet; Audrey Vincent; Sylvain Lehoux; Jean-Jacques Lafitte; Isabelle Van Seuningen; Philippe Delannoy
Journal:  Biochem J       Date:  2008-02-15       Impact factor: 3.857

Review 8.  Defective acidification of the biosynthetic pathway in cystic fibrosis.

Authors:  J Barasch; Q al-Awqati
Journal:  J Cell Sci Suppl       Date:  1993

9.  MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.

Authors:  Markus O Henke; Armin Renner; Rudolf M Huber; Michael C Seeds; Bruce K Rubin
Journal:  Am J Respir Cell Mol Biol       Date:  2004-02-26       Impact factor: 6.914

10.  Reactive oxygen species mediate inflammatory cytokine release and EGFR-dependent mucin secretion in airway epithelial cells exposed to Pseudomonas pyocyanin.

Authors:  B Rada; P Gardina; T G Myers; T L Leto
Journal:  Mucosal Immunol       Date:  2010-10-20       Impact factor: 7.313

View more
  80 in total

Review 1.  Cystic fibrosis: an inherited disease affecting mucin-producing organs.

Authors:  Camille Ehre; Caroline Ridley; David J Thornton
Journal:  Int J Biochem Cell Biol       Date:  2014-03-28       Impact factor: 5.085

2.  Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.

Authors:  Mark Bazett; Lisa Honeyman; Anguel N Stefanov; Christopher E Pope; Lucas R Hoffman; Christina K Haston
Journal:  Mamm Genome       Date:  2015-02-27       Impact factor: 2.957

3.  Pituitary adenylate cyclase-activating polypeptide is a potent broad-spectrum antimicrobial peptide: Structure-activity relationships.

Authors:  Charles G Starr; Jerome L Maderdrut; Jing He; David H Coy; William C Wimley
Journal:  Peptides       Date:  2018-04-11       Impact factor: 3.750

4.  Acid exposure disrupts mucus secretion and impairs mucociliary transport in neonatal piglet airways.

Authors:  Yan Shin J Liao; Shin Ping Kuan; Maria V Guevara; Emily N Collins; Kalina R Atanasova; Joshua S Dadural; Kevin Vogt; Veronica Schurmann; Laura Bravo; Eda Eken; Mariana Sponchiado; Leah R Reznikov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-11       Impact factor: 5.464

5.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

6.  Cystic fibrosis transmembrane conductance regulator function, not TAS2R38 gene haplotypes, predict sinus surgery in children and young adults with cystic fibrosis.

Authors:  Nicholas M Dalesio; Melis A Aksit; Kwangmi Ahn; Karen S Raraigh; Joseph M Collaco; Sharon McGrath-Morrow; Pamela L Zeitlin; Steven S An; Garry R Cutting
Journal:  Int Forum Allergy Rhinol       Date:  2020-04-13       Impact factor: 3.858

7.  KChIP3 coupled to Ca2+ oscillations exerts a tonic brake on baseline mucin release in the colon.

Authors:  Gerard Cantero-Recasens; Cristian M Butnaru; Miguel A Valverde; José R Naranjo; Nathalie Brouwers; Vivek Malhotra
Journal:  Elife       Date:  2018-10-01       Impact factor: 8.140

8.  Sodium channel TRPM4 and sodium/calcium exchangers (NCX) cooperate in the control of Ca2+-induced mucin secretion from goblet cells.

Authors:  Gerard Cantero-Recasens; Cristian M Butnaru; Nathalie Brouwers; Sandra Mitrovic; Miguel A Valverde; Vivek Malhotra
Journal:  J Biol Chem       Date:  2018-11-27       Impact factor: 5.157

9.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

10.  Defective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease.

Authors:  Jinghua Liu; Nancy M Walker; Akifumi Ootani; Ashlee M Strubberg; Lane L Clarke
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.